What pharmacologic treatment options and dosing are recommended for managing stimulant use disorder, including monitoring considerations?

Medication Recommendation for Stimulant Use Disorder

Contingency management is the current standard of care for stimulant use disorder, and while no FDA-approved pharmacotherapy exists, prescription psychostimulants—particularly prescription amphetamines (mixed amphetamine salts, dextroamphetamine, or lisdexamphetamine) at robust doses—show the most promise for promoting abstinence, especially in cocaine use disorder. 1

Current Evidence-Based Treatment Framework

First-Line Treatment: Behavioral Interventions

• Contingency management represents the established standard of care and should be implemented as the foundation of treatment 1
• Cognitive behavioral therapy and motivational interviewing provide additional benefit 2
• These psychosocial interventions remain the primary treatment modality given the absence of FDA-approved medications 3

Pharmacotherapy Options (Off-Label)

For Cocaine Use Disorder:

• Prescription amphetamines (mixed amphetamine salts, dextroamphetamine, or lisdexamphetamine) show the strongest evidence

  • Doses: 60-110 mg/day dextroamphetamine or equivalent 4
  • Evidence: Increases sustained abstinence rates (RR = 2.44) and produces 8.37% more cocaine-negative urines 5
  • Higher doses (≥60 mg/day equivalent) are more effective than lower doses 5
  • Treatment duration ≥20 weeks associated with better retention 4

• Methylphenidate as alternative option

  • Doses: 54-180 mg/day 4
  • Moderate-quality evidence for reducing cocaine use 5

For Methamphetamine/Amphetamine-Type Stimulant Use Disorder:

• Methylphenidate: 54-180 mg/day for 2-24 weeks 4
• Dextroamphetamine: 60-110 mg/day 4
• Evidence shows decreased craving (SMD -0.29) and potential reduction in amphetamine use, though effect sizes are more limited than for cocaine 4

Dosing Strategy

1. Start with moderate doses and titrate upward based on response
2. Target robust doses for optimal efficacy (higher doses show better outcomes) 5
3. Continue treatment for minimum 20 weeks for best retention rates 4
4. Monitor for cardiovascular effects, particularly hypertension and tachycardia

Monitoring Considerations

• Baseline assessment: Blood pressure, pulse, cardiac history, psychiatric comorbidities
• Ongoing monitoring:
  • Vital signs at each visit (blood pressure and pulse particularly important)
  • Urine drug screens to assess treatment response
  • Craving scales and functional assessments
  • Screen for stimulant-induced psychosis, depression, and suicidal ideation
  • Cardiovascular symptoms (palpitations, chest pain)

Important Clinical Caveats

Contraindications to prescription stimulants:

• Active psychotic disorder
• Uncontrolled hypertension or significant cardiovascular disease
• Current MAO inhibitor use
• Active diversion risk without adequate supervision 6

Key Pitfall: The evidence quality remains limited overall (very low to moderate quality) 5, and prescription stimulants are not FDA-approved for stimulant use disorder. However, given the lack of approved alternatives and the significant morbidity/mortality of untreated stimulant use disorder, off-label use of prescription amphetamines at robust doses represents the most evidence-based pharmacologic approach when combined with contingency management 1.

Population-Specific Considerations:

• Prescription amphetamines show particular efficacy in cocaine use disorder specifically 5
• Evidence for methamphetamine use disorder is less robust but shows promise with methylphenidate 4
• Patients with co-occurring opioid use disorder may benefit from buprenorphine, which has shown some efficacy for stimulant use disorder 7

Harm Reduction Strategies

• Provide naloxone for overdose prevention (particularly with polysubstance use)
• Offer fentanyl test strips given contamination of stimulant supply 1
• Address acute complications: hyperthermia, rhabdomyolysis, cardiovascular emergencies, and stimulant-induced psychosis 8

The bottom line: While contingency management remains the gold standard, prescription amphetamines at doses of 60-110 mg/day (or equivalent) combined with behavioral interventions offer the best pharmacologic option for promoting abstinence, particularly in cocaine use disorder, despite the absence of FDA approval 5, 1.